To study the mechanism of cetuximab resistance in KRAS wild-type colorectal cancer (CRC) patients, scientists evaluated the impact of circIFNGR2 on CRC and detected the association among circIFNGR2, miR-30b, and KRAS via various experiments such as RT-qPCR, immunohistochemistry, luciferase assays, cell functional experiments and xenograft model.
[Cell Death & Disease]